In-hospital management of type 2 diabetes mellitus

Medical Clinics of North America

Volumn 88, Issue 4, 2004, Pages 1085-1105

  Lien, Lillian F ^a   Angelyn Bethel, M ^a   Feinglos, Mark N ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLCYSTEINE; ADRENALIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; STEROID; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE COURSE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TOXICITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

ADMINISTRATION, ORAL; AGED; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; INSULIN; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT CARE TEAM; PATIENT EDUCATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 4143088407     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.04.002     Document Type: Review

References (66)

1. Henriksson F., Agardh C., Berne C., Bolinder J., Lonnqvist F., Stenstrom P., et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med. 248:2000;387-396
2. Bhattacharyya S., Else B. Medical costs of managed care in patients with type 2 diabetes mellitus. Clin Ther. 21:(12):1999;2131-2142
3. O'Brien J, Shomphe L, Kavanagh P, Raggio G, Caro J. Direct medical costs of complications resulting from type 2 diabetes in the US Diabetes Care 1998;21(7):1122-8.
4. Levetan C., Magee M. Hospital management of diabetes. Endocrinol Metab Clin North Am. 29:(4):2000;745-770
5. Jarrett R., Shipley M. Type 2 (non-insulin dependent) diabetes mellitus and cardiovascular disease - putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia. 31:1988;737-740
6. Erkens J., Klungel O., Stolk R., Spoelstra J., Grobbree D., Leufkens H. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care. 24:(8):2001;1428-1432
7. Donnan P., Leese G. Morris A for the DARTS/MEMO Collaboration. Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. Diabetes Care. 23:(12):2000;1774-1779
8. Moss S., Klein R., Klein B. Risk factors for hospitalization in people with diabetes. Arch Intern Med. 159:1999;2053-2057
9. Yellin A., Refaely Y., Paley M., Simansky D. Major bleeding complicating deep sternal infection after cardiac surgery. J Thorac Cardiovasc Surg. 125:2003;554-558
10. Berger A., Breall J., Gersh B., Johnson A., Oetgen W., Marciniak T., et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the cooperative cardiovascular project). Am J Cardiol. 87:2001;272-277
11. Donnan P., Boyle D., Broomhall J., Hunter K., MacDonald T., Newton R., et al. for the DARTS/MEMO collaboration. Prognosis following first acute myocardial infarction in type 2 diabetes: a comparative population study. Diabet Med. 19:2002;448-455
12. Feddersen E., Lockwood D. An inpatient diabetes educator's impact on length of hospital stay. Diabetes Educ. 20:(2):1994;125-128
13. Davies M., Dixon S., Currie C., Davis R., Peters J. Evaluation of a hospital diabetes specialist nursing Service: a randomized controlled trial. Diabet Med. 18:2001;301-307
14. Levetan C., Salas J., Wilets I., Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med. 99:(1):1995;22-28
15. Umpierrez G.E., Isaacs S.D., Bazargan N., You X., Thaler L.M., Kitabchi A.E. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 87:(3):2002;978-982
16. Luna B., Feinglos M.N. Drug-induced hyperglycemia. JAMA. 286:2001;1945-1948
17. Hirsch I., Paauw D., Brunzell J. Inpatient management of adults with diabetes. Diabetes Care. 18:(6):1995;870-878
18. Malmberg K., Ryden L., Efendic S., Herlitz J., Nicol P., Waldenstrom A., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardio. 26:1995;57-65
19. Malmberg K., Norhammar A., Wedel H., Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation. 99:(20):1999;2626-2632
20. Furnary A.P., Gao G., Grunkemeier G.L., Wu Y., Zerr K.J., Bookin S., et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 125:2003;1007-1021
21. Furnary A.P., Zerr K.J., Grunkemeier G.L., Starr A. Continuous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 67:1999;352-362
22. Zerr K.J., Furnary A.P., Grunkemeier G.L., Bookin S., Kanhere V., Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operation. Ann Thorac Surg. 63:1997;356-361
23. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 345:2001;1359-1367
24. Anonymous. (A.D.A.). Summary of recommendations for adults with diabetes mellitus. Diabetes Care. 26:(Suppl. 1):2003;S33-S50
25. Clement S., Braithwaite S., Magee M., Ahmann A., Smith E., Schafer R., et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 27:(2):2004;553-591
26. Levetan C., Passaro M., Jablonski K., Kass M., Ratner R. Unrecognized diabetes among hospitalized patients. Diabetes Care. 21:(2):1998;246-249
27. Belfiore F., Iannello S. Insulin treatment in Type 1 and Type 2 diabetes: practical goals and algorithms. Belfiore F., Mogensen C. New Concepts in Diabetes and Its Treatment. 2000;72-89 Karger, Basil
28. American Diabetes Association. Multiple-component insulin regimens. Farkas-Hirsch R. Intensive diabetes management. 1995;51-64 ADA, Inc, Alexandria, VA
29. Nathan M., Leahy J. Insulin management of hospitalized diabetic patients. Leahy J., Cefalu W. Insulin therapy. 2002;153-172 Marcel Dekker, Inc, New York
30. Nathan D. Insulin treatment of type 2 diabetes mellitus. Prote D., Sherwin R., Baron A. Ellenberg & Rifkin's diabetes mellitus. 6th edition :2003;515-522 McGraw-Hill, New York
31. Hamann A., Matthaei S., Rosak C., Silvestre L., for the HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 26:(6):2003;1738-1744
32. Wittlin S., Woehrle H., Gerich J. Insulin pharmacokinetics. Leahy J., Cefalu W. Insulin therapy. 2002;73-85 Marcel Dekker, Inc, New York
33. American Diabetes Association. Insulin infusion pump therapy. Farkas-Hirsch R. Intensive diabetes management. 1995;65-78 ADA, Inc, Alexandria, VA
34. Lilley S., Levine G. Management of hospitalized patients with type 2 diabetes mellitus. Am Fam Physician. 57:(5):1998;1079-1088
35. Trence D.L., Kelly J.L., Hirsch I.B. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab. 88:2003;2430-2437
36. Lien L., Spratt S., Woods Z., Osborne K., Feinglos M. A new intravenous insulin nomogram in intensive care units improves management of persistent hyperglycemia. Diabetes. 52:(Suppl 1):2003;A125
37. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 24:(4):2001;758-767
38. Bailey C.J., Turner R.C. Metformin. N Engl J Med. 334:(9):1996;574-579
39. Rose BD, Post TW, Narins RG. Causes of lactic acidosis. In: Rose BD, editor. UpToDate. Wellesley, MA; 2003.
40. Feinglos M.N., Bethel M.A. Treatment of type 2 diabetes mellitus. Med Clin N Am. 82:(4):1998;757-790
41. Stang M., Wysowski D.K., Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 22:(6):1999;925-927
42. Glucophage (metformin hydrochloride){package insert}. Princeton, NF: Bristol-Myers Squibb; December 1998.
43. Masoudi F.A., Wang Y., Inzucchi S.E., Setaro J.F., Havranek E.P., Foody J.M., et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 290:(1):2003;81-85
44. Calabrese A.T., Coley K.C., DaPos S.V., Swanson D., Rao H. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 162:(4):2002;434-437
45. Emslie-Smith A.M., Boyle D.I.R., Evans J.M.M., Sullivan F., Morris A.D. Contraindication to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med. 18:(6):2001;483-488
46. Salpeter S, Greyber E, Pasternak G, Salpeter E, editors. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane database of systematic reviews 2003. Vol 1.
47. Pond G.D., Smyth S.H., Roach D.J., Hunter G. Metformin and contrast media: genuine risk or witch hunt? Radiology. 201:(3):1996;879-880
48. Tadros G.M., Mouhayar E.N., Akinwande A.O., Campbell B., Wood C., Blankenship J.A. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol. 15:(6):2003;311-314
49. Kay J., Chow W.H., Chan T.M., Lo S.K., Kwok O.H., Yip A., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 289:(5):2003;553-558
50. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W. Prevention of radiographic- contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 343:(3):2000;180-184
51. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: mortality results. Diabetes. 19:1970;785-830
52. Feinglos M.N., Bethel M.A. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J. 138:(Suppl 5):1999;S346-S352
53. O'Rourke B. Myocardial K-ATP channels in preconditioning. Circ Res. 87:(10):2000;845-855
54. Lee T.-M., Chou T.-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 88:(2):2002;531-537
55. Scognamiglio R., Avogaro A., Vigili de Kreutzenberg S., Negut C., Palisi M., Bagolin E., et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes. 51:(3):2002;808-812
56. Riddle M. Editorial: Sulfonylureas differ in effects on ischemic preconditioning - is it time to retire glyburide? J Clin Endocrinol Metab. 88:(2):2003;528-530
57. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:(12):1996;1661-1669
58. Ogino K., Furuse Y., Uchida K., Shimoyama M., Kimugawa T., Osaki S., et al. Troglitazone improves cardiac function in patients with congestive heart failure. Cardiovasc Drugs Ther. 16:(3):2002;215-220
59. Shiomi T., Hiroyuki T., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 106:(24):2002;3126-3132
60. Masoudi F.A., Wang Y., Enzucchi S.E., Setaro J., Havranek E.P., Foody J.M., et al. Metformin and thiazolidinedione use in medicare patients with heart failure. JAMA. 290:(1):2003;81-85
61. Delea T., Hagiwara M., Edelsberg J., Oster G. Exposure to glitazone antidiabetics and risk of heart failure among persons with type 2 diabetes: a retrospective population-based cohort analysis (abstr.). J Am Coll Cardiol. 39:(Suppl):2002;184A
62. Tang W.H.W., Francis G.S., Hoogwerf B.J., Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 41:(8):2003;1394-1398
63. American Diabetes Association. Translation of the diabetes nutrition recommendations for health care institutions. Diabetes Care. 26:(Suppl 1):2003;S70-S72
64. Surwit R., Schneider M., Feinglos M. Stress and diabetes mellitus. Diabetes Care. 15:1992;1413-1422
65. Davis E., Midgett L., Gourley C. Teach less, teach better at every opportunity. Diabetes Educ. 20:(3):1994;236-240
66. NovoLog Mix 70/30 [prescribing information and information pamphlet]. April 2003;Novo Nordisk Pharmaceuticals, Inc, Princeton, NJ